Previous 10 | Next 10 |
2024-03-20 19:35:23 ET Start Time: 16:30 End Time: 17:11 HeartBeam, Inc. (BEAT) Q4 2023 Earnings Conference Call March 20, 2024, 16:30 PM ET Company Participants Branislav Vajdic - CEO and Founder Rob Eno - President Deborah Castillo - VP of Regulatory Af...
2024-03-20 16:16:01 ET More on HeartBeam HeartBeam gains on receipt of two US patents for its core cardiac monitoring technology Seeking Alpha’s Quant Rating on HeartBeam Historical earnings data for HeartBeam Financial information for HeartBeam ...
First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing Clinical and Regulatory Progress for the AIMIGo 3D VECG System Recently Received 2 New Patents for our Proprietary Technologies Management to Host W...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Speciali...
VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patient...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent a...
2024-03-07 09:01:15 ET More on HeartBeam Seeking Alpha’s Quant Rating on HeartBeam Historical earnings data for HeartBeam Financial information for HeartBeam Read the full article on Seeking Alpha For further details see: HeartBeam gains on...
Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received t...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slate...
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...